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Standard Chemotherapy With or Without High-Dose
Chemotherapy for Aggressive Non-Hodgkin’s
Lymphoma: Randomized Phase III EORTC Study
Hanneke C. Kluin-Nelemans, Vittorina Zagonel, Anastasia Anastasopoulou,
Dominique Bron, Klaas J. Roozendaal, Ed M. Noordijk, Helen Musson, Ivana
Teodorovic, Brigitte Maes, Antonino Carbone, Patrice Carde, Jose´ Thomas
Background: The long-term outcome for patients with ag-
gressive non-Hodgkin’s lymphoma (NHL) is poor. Conse-
quently, the European Organization for Research and Treat-
ment of Cancer Lymphoma Group designed a prospective
randomized trial to investigate whether high-dose chemo-
therapy plus autologous bone marrow transplantation
(ABMT) after standard combination chemotherapy im-
proves long-term survival. Methods: Patients aged 15–65
years with aggressive NHL received three cycles of CHVmP/BV
polychemotherapy (i.e., a combination of cyclophosphamide,
doxorubicin, teniposide, and prednisone, with bleomycin and
vincristine added at mid-cycle). After these three cycles, pa-
tients with a complete or partial remission and at that time
no lymphoma involvement in the bone marrow were ran-
domly assigned to the ABMT arm (a further three cycles of
CHVmP/BV followed by BEAC [i.e., a combination of car-
mustine, etoposide, cytarabine, and cyclophosphamide] che-
motherapy and ABMT) or to the control arm (five more
cycles of CHVmP/BV). All statistical tests are two-sided.
Results: From December 1990 through October 1998, 311
patients (median age = 44 years) were registered and re-
ceived the first three cycles of CHVmP/BV, and 194 patients
were randomly assigned to the treatment arms. Approxi-
mately 70% (140 patients) of these patients were of low or
low–intermediate International Prognostic Index (IPI) risk.
After a median follow-up of 53 months, an intention-to-treat
analysis showed a time to disease progression and overall
survival at 5 years of 61% (95% confidence interval [CI] =
51% to 72%) and 68% (95% CI = 57% to 79%), respec-
tively, for the ABMT arm and 56% (95% CI = 45% to 67%)
and 77% (95% CI = 67% to 86%), respectively, for the
control arm. Differences between arms were not statistically
significant. A subset analysis on IPI risk groups, although
too small for reliable statistical analysis, yielded similar re-
sults. Conclusions: Standard combination therapies remain
the best choice for most patients with aggressive NHL. We
recommend that patients with IPI low or low–intermediate
risk not be subjected to high-dose chemotherapy and ABMT
as a first-line therapy. [J Natl Cancer Inst 2001;93:22–30]
Patients with advanced aggressive non-Hodgkin’s lymphoma
(NHL) can be treated effectively with multiagent chemotherapy.
Although the majority of patients younger than the age of 65
years will reach a complete remission (CR) after CHOP-like
chemotherapy (i.e., combination chemotherapy with cyclophos-
phamide, doxorubicin, vincristine, and prednisone), fewer than
50% will be finally cured (1). More intensive chemotherapy
regimens (2–5) generally yielded high percentages of CR, up to
80%, but did not improve the disease-free survival when com-
pared with the results with CHOP: In a large randomized trial
comparing three intensive chemotherapy regimens with classical
CHOP, no difference was found among the four regimens (6).
In 1975, the European Organization for Research and Treat-
ment of Cancer (EORTC) designed CHVmP, a polychemo-
therapy regimen derived from CHOP, consisting of courses of
cyclophosphamide, doxorubicin, teniposide, and prednisone re-
peated every 3 weeks, for patients with NHL. In the second-
generation EORTC trial for patients with stage III or IV NHL
who were aged up to 70 years, with intermediate- and high-grade
malignancy [Working Formulation (7)], CHVmP alone was
compared with CHVmP to which bleomycin and vincristine
were added at mid-cycle (CHVmP/BV). The CHVmP/BV
scheme resulted in a higher rate of CR (74% versus 49%) with
a better overall survival at 5 years (53% versus 29%) (8) and 10
years (34% versus 22%) (9). The next EORTC randomized
study that compared CHVmP/BV with the third-generation regi-
men ProMACE-MOPP (i.e., a combination of prednisone,
methotrexate, doxorubicin, cyclophosphamide, and etoposide,
followed by mechlorethamine, vincristine, procarbazine, and
prednisone) found identical survival between the two arms but
with far less toxicity for patients in the CHVmP/BV arm (10).
In the mid-1980s, high-dose chemotherapy followed by au-
tologous stem cell rescue became a mature therapy option that
had activity for relapsing and refractory NHL (11–14). Obvi-
ously, dose escalation appeared to cure some patients with con-
ventional chemotherapy-resistant disease. In large overviews
covering more than 1200 patients, Goldstone et al. (15) and
Armitage (16) documented that this form of bone marrow abla-
tive therapy resulted in long-term disease-free survival in more
than half of the patients who received a transplant at a time of
minimal disease early in the course of their lymphoma. How-
ever, selection might have played a major role in the outcome of
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these patients because none of these patients had been treated in
randomized phase III trials.
Therefore, in 1990, with the aim of improving the outcome of
patients with aggressive NHL, the EORTC Lymphoma Group
designed a prospective randomized study (EORTC 20901) com-
paring the EORTC gold-standard regimen (eight cycles of
CHVmP/BV) with six cycles of CHVmP/BV followed by con-
solidation BEAC (i.e., a combination of carmustine, etoposide,
cytarabine, and cyclophosphamide) high-dose chemotherapy.
The bone marrow ablative therapy was given to patients who
had reached a minimal residual disease status. Herein, we pre-




Newly diagnosed patients aged 15–60 years with NHL of stages II–IV were
registered. After 1997, the upper age limit was increased to 65 years because
of slow accrual and the fact that the transplant procedure was well tolerated in
the eldest patients of the cohort. For inclusion, the criteria of the Working
Formulation (7) for NHL had to be fulfilled and the lymphoma had to be of
intermediate-grade histology (categories D, E, F, and G). In addition, patients
with stage I bulky NHL or stages II–IV of the following types were acceptable:
diffuse large-cell immunoblastic lymphoma, anaplastic large-cell lymphoma,
large-cell and small-cell (if containing numerous blasts) pleomorphic T-cell
lymphoma, and angioimmunoblastic lymphoma with dysproteinemia-like T-cell
lymphoma. Patients with low-grade NHL, lymphoblastic NHL, and Burkitt’s
lymphoma were excluded. Staging evaluation included a full hematologic and
chemical laboratory survey, a chest x-ray, a computerized tomography scan of
the thorax and abdomen, a bone marrow biopsy, an ear, nose, and throat con-
sultation, and, if indicated, additional studies, such as endoscopy, bone scan, or
cerebrospinal fluid analysis. In addition, a cardiac ejection fraction at rest and
pulmonary function studies, including spirometry and carbon monoxide diffu-
sion measurements, were performed. Patients were required to have a World
Health Organization (WHO) performance status of 2 or less without severe
cardiac, pulmonary, neurologic, or metabolic disease. The patients gave in-
formed consent for both registration and randomization according to the rules of
the local center.
Pathology
A diagnosis based on good-quality histology and made by the local pathologist
was accepted. Directly after registration, the local pathologist was required to
send in six unstained slides for central pathology review. The final classifying
diagnosis was based on the central review and was made according to the revised
European–American lymphoma (REAL) classification (17).
Study Design and CHVmP/BV Therapy
The study design is shown in Fig. 1. Patients who had achieved a CR or a
partial remission (PR) after the first three cycles of CHVmP/BV were randomly
assigned to treatment. Each cycle (3-week duration) of CHVmP/BV chemo-
therapy consisted of cyclophosphamide at a dose of 600 mg/m2, doxorubicin at
50 mg/m2, and teniposide at 60 mg/m2 given intravenously on day 1, with
prednisone at 40 mg/m2 given orally on days 1, 2, 3, 4, and 5. On day 15,
bleomycin at 10 mg (in total) and vincristine at 1.4 mg/m2 (to a maximum of 2
mg) were given intravenously.
The following dose adaptations were advised: Full doses were always given in
the first course, irrespective of the initial blood cell counts. Subsequent courses
were postponed for 1 week if, at day 1, there were fewer than 3 × 106 leukocytes/
mL or fewer than 100 × 106 thrombocytes/mL. If, after 1 week, cytopenia had
not recovered, the three intravenously administered drugs were given at 75%
(3–4 × 106 leukocytes/mL) or 50% (2–3 × 106 leukocytes/mL or 50–100 × 106
platelets/mL). If the counts were lower than these values, only prednisone,
vincristine, and bleomycin were given. Bone marrow depression was never a
reason to adjust the doses of bleomycin and vincristine. These drugs were ad-
justed only when pulmonary (bleomycin) or neurologic (vincristine) toxicity was
observed.
All patients received three cycles of treatment and were evaluated after the
third full course. If patients had a CR or a PR without histologically proven
lymphoma involvement in the bone marrow after the third cycle and were
without contraindications for bone marrow ablative chemotherapy (WHO per-
formance status of 0 or 1; no problems harvesting bone marrow or no severe
cardiac, pulmonary, neurologic, infectious, or metabolic disease), they were
randomly assigned to the autologous bone marrow transplantation (ABMT) arm
or to the control arm. Patients in the ABMT arm received three more cycles of
CHVmP/BV, followed by BEAC chemotherapy and autologous stem cell rescue.
Patients in the control arm received five more cycles of CHVmP/BV. Before
BEAC chemotherapy, the following eligibility criteria had to be fulfilled: CR or
PR, performance status of 0 or 1, no lymphoma infiltration in the bone marrow
at the time of stem cell harvest, adequate numbers of frozen stem cells (see
below), a cardiac ejection fraction of 0.5 or more, a vital capacity of 70% or more
of predicted value, a carbon dioxide diffusion capacity of 50% or more, and the
absence of other factors compromising the aplasia period. If these criteria were
not fulfilled, the patient was treated according to the control arm scheme.
Radiotherapy
For patients who had a PR after standard chemotherapy, radiotherapy was
mandatory. All areas with macroscopically residual disease after eight cycles of
Fig. 1. Outline of the European Organization for Research and Treatment of Cancer 20901 study. NHL  non-Hodgkin’s lymphoma; CHVmP/BV  polyche-
motherapy regimen given every 3 weeks (a combination of cyclophosphamide, doxorubicin, teniposide, and prednisone, with bleomycin and vincristine added at
mid-cycle); CR–PR  complete remission–partial remission; BM  bone marrow; BEAC  a combination of carmustine, etoposide, cytarabine, and cyclophos-
phamide. BM +  positive, i.e., with lymphoma involvement.
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CHVmP/BV were irradiated (30-Gy total dose on the whole area, followed by a
10-Gy boost on the residual disease site). Radiotherapy started within 3–4 weeks
after the end of the last chemotherapy.
For patients in the control arm who had a CR at the end of chemotherapy,
additional iceberg radiotherapy according to EORTC usage was advised (but was
not mandatory). Iceberg radiotherapy is defined as radiotherapy (30 Gy) for all
areas with disease with an initial diameter greater than 5 cm and for areas with
macroscopically residual disease after three cycles of CHVmP/BV. Radio-
therapy after ABMT was left to the discretion of the physician but was advised
for those patients with bulky mediastinal lymphomas. Iceberg radiotherapy
started within 3–4 weeks after the end of chemotherapy.
Autologous Stem Cell Transplantation and BEAC Therapy
Stem cells were harvested after patients were randomly assigned to treatment,
preferably between the fourth and sixth cycles of CHVmP/BV. In most patients,
a total of 2–3 × 108 bone marrow cells per kilogram of body weight were
harvested. During the later years of the study, stem cell harvesting from periph-
eral blood was permitted, but only if granulocyte colony-stimulating factor or
granulocyte–macrophage colony-stimulating factor given after the CHVmP/BV
chemotherapy was used as a sole factor to induce stem cell mobilization. Ad-
ditional chemotherapy was not permitted to facilitate stem cell mobilization.
ABMT had to be performed within 6 weeks after the last chemotherapy course.
As pretransplant measures, the protocol advised the use of a central venous
catheter, parenteral nutrition when oral energy intake became insufficient, partial
antibiotic (scheme according to the rules of the local center) decontamination of
the digestive tract, and a stay in a laminar air flow room. Decontamination
procedures started approximately 1 week before the BEAC regimen was initi-
ated. Decontamination was discontinued according to the rules of the local center
but not before the patient had a minimum of 0.5 × 106 granulocytes/mL, mea-
sured on 2 consecutive days. Hematologic supportive care involved prophylactic
leukocyte-poor (filtered) platelet transfusions at least when there were fewer than
10 × 106 platelets/mL as well as therapeutic transfusions when clinically indi-
cated. Filtrated packed red blood cells were used to maintain a hemoglobin
concentration greater than 10 g/dL. All blood products were irradiated (15 Gy).
BEAC chemotherapy (18) consisted of carmustine at a dose of 300 mg/m2
given intravenously on day 1; etoposide at a dose of 200 mg/m2 given intrave-
nously on days 2, 3, 4, and 5; cytarabine at a dose of 200 mg/m2 given intra-
venously on days 2, 3, 4, and 5; and cyclophosphamide at a dose of 35 mg/kg
given intravenously on days 2, 3, 4, and 5 with detoxification using mesna
(sodium 2-mercaptoethane sulfonate) at 20 mg/kg (given 10 minutes before and
4, 8, 12, and 16 hours after cyclophosphamide). After a 1-day rest (day 6), stem
cells were reinfused on day 7.
Registration and Randomization
All patients were registered and randomly assigned at the EORTC Data Center
by Internet (EUROCODE program) or by telephone. Patients were randomly
assigned by use of the minimization technique with the institution number as the
only factor for stratification, which resulted in 50% of the assignments being
deterministic. Because there were no known prognostic factors at the time of
protocol development, no other factor was used. At registration and at random-
ization, the inclusion/exclusion criteria were verified and had to be fulfilled
before any patient was accepted. All patients had to be registered before the start
of chemotherapy.
Data Management
Double entry of all data, collected on case report forms, was performed.
Cross-checks for missing forms and inconsistent data were done throughout the
study according to standard operating procedures of the EORTC Data Center.
Twice a year, the study coordinator (H. C. Kluin-Nelemans) evaluated the pa-
tients’ files at the Data Center.
Response Evaluation
The disease in all patients was restaged after three cycles, after six cycles
(ABMT arm), or after eight cycles (control arm) of CHVmP/BV and after
completion of the final treatment (BEAC and/or radiotherapy). All initially in-
volved sites had to be measured and documented. The response to treatment was
assessed according to the WHO criteria (19).
End Points and Statistical Considerations
Time to disease progression and overall survival were the end points used.
Time to disease progression is the time between the date of randomization to the
date of disease progression. If progression was not observed, the patient was
censored at the date of the last examination. Overall survival is the time between
the date of randomization and the date of death from any cause. Patients who
were still alive when last contacted were censored at the date of last follow-up.
For the patients who were not randomly assigned, the overall survival was
calculated as the time between the date of registration and the date of death. One
hundred assessable patients were to be randomly assigned to each therapeutic
arm, which would ensure enough relapses 5 years after the last randomization to
detect a difference of 20% (from 50% to 70%) in the median time to disease
progression (  0.05;   0.2). We assumed that 66% of the registered
patients were eligible and randomly assigned, necessitating 300 patients for
registration. All analyses of the randomly assigned patients were done on an
intention-to-treat basis. Survival curves were estimated by use of the Kaplan–
Meier method (20) and compared by use of the log-rank test (21,22). All sta-
tistical tests used were two-sided.
Interim Analysis
The protocol did not foresee an interim analysis or an Independent Data
Monitoring Committee. However, because of a decrease in the accrual from
1995 onward, the EORTC Protocol Review Committee permitted an interim
analysis. This analysis was performed in October 1998, with the software pack-
age EaST (CYTEL Software Corporation) to test whether there was sufficient
evidence for (or against) the effectiveness of the ABMT treatment and to deter-
mine whether the study should be continued. The O’Brien–Fleming stopping
rule (23) was applied, and the log-rank test (24,25) was performed. At that time,
307 patients had been registered and 181 patients had been randomly assigned.
The aim was to detect a hazard ratio of 0.515 with a power of 80% and a nominal
statistical significance level of 5% (two-sided test) in the time to progression.
The analysis was performed by the EORTC Data Center and discussed by an
Independent Data Monitoring Committee, consisting of non-EORTC members.
After the group committed to follow the advice of the Independent Data Moni-
toring Committee, the results were disclosed on October 17, 1998.
RESULTS
Interim Analysis Results
The O’Brien–Fleming stopping rule for boundaries following
an alpha spending function approach (23) was applied as appro-
priate for cancer clinical trials. At the time of the interim analy-
sis, 56 of the 80 events required had occurred, and the critical
value of the test statistic was 0.813 [(O − E)/(V)1/2, where Z ∼
N(0,1), O is the observed number, E is the expected number, V
is the variance, Z is a random variable that is distributed as a
standardized normal distribution with a mean of 1 and a variance
of 1, and N is the normal distribution]. With the use of a shape
parameter of 0.0 and given the previous number of events, the
boundary values of 2.29 to reject the null hypothesis (H0) and
1.33 to reject the alternative hypothesis (H1) were calculated.
Because the critical value of the test statistic was smaller than
the value to reject H1 (0.813 < 1.33), the Independent Data
Monitoring Committee advised that the study be stopped owing
to evidence of a lack of effectiveness of the ABMT treatment
over the control therapy. Patients who had been registered
shortly before October 1998 were not allowed to undergo the
randomization procedure; instead, they received the control arm
therapy.
Final Analysis Results
This analysis used a median follow-up of 53 months (range
 47–58 months) for randomly assigned patients. Data entry
24 ARTICLES Journal of the National Cancer Institute, Vol. 93, No. 1, January 3, 2001
Downloaded from https://academic.oup.com/jnci/article-abstract/93/1/22/2906101
by University of Groningen user
on 14 May 2018
was closed on December 31, 1999. From December 1990
through October 1998, 311 patients were registered (Table 1).
The classification of pathology, initially based on the Working
Formulation (7), was reclassified according to the REAL clas-
sification (17) and is shown in Table 2. On the basis of a central
review of the pathology, 18 patients (12 with follicular lym-
phoma and six with Burkitt’s lymphoma) were considered to be
ineligible. Nevertheless, all patients were analyzed on the basis
of the intention-to-treat principle.
Protocol Adherence
Patients could be randomly assigned only if they had re-
sponded after three cycles and had no lymphoma involvement in
the bone marrow. Transplantation after the sixth cycle could be
performed only in the absence of contraindications for bone
marrow ablative chemotherapy (i.e., patients whose disease re-
lapsed or progressed during cycles 4–6 or who developed toxic
effects or other conditions compromising the aplasia period were
not allowed to undergo the high-dose chemotherapy). The latter
group received—according to the protocol—the complete eight
cycles of treatment given to the control arm. The protocol ad-
herence is summarized in Table 3. A total of 194 patients were
randomly assigned: 98 patients to the ABMT arm and 96 pa-
tients to the control arm. The clinical characteristics, including
the International Prognostic Index (IPI) risk profile, and pathol-
ogy subgroups were well balanced between the arms. Approxi-
mately 70% (140 patients) belonged to the low- or low–intermediate-
IPI-risk category (Tables 1 and 2). The reasons why 117 patients
were not randomly assigned are given in Table 3. Of these
patients, 86 received the chemotherapy according to the control
arm, five received high-dose chemotherapy followed by stem
cell transplantation, eight received other chemotherapy, two re-
ceived radiotherapy, and two were not treated at all. We had no
information from 14 patients.
Of 98 patients randomly assigned to undergo the high-dose
chemotherapy, 61% were treated accordingly. Thirteen of these
98 patients belonged to the IPI high–intermediate-risk group and
two belonged to the IPI high-risk group. Two more were con-
ditioned by BEAM (BEAC except that cyclophosphamide is
replaced with melphalan) instead of BEAC. The reasons why 38
patients did not undergo the transplant procedure are given in
Table 3. Apart from those patients who had a relapse while on
CHVmP/BV, most other patients in the ABMT arm who did not
get BEAC were treated according to the protocol by the control
arm and received five more cycles of CHVmP/BV instead. Only
two patients randomly assigned to the control arm received au-
tologous stem cell transplantation as consolidation therapy.
Radiotherapy
Of 37 patients in PR after eight cycles of CHVmP/BV, 31
received radiotherapy (22 patients from the control arm, five
patients from the ABMT arm, and four patients in the group that
had not been randomly assigned to treatment). The disease status
of 10 patients (32%) subsequently converted from PR to CR.
Iceberg radiotherapy was optional according to the protocol and
was given to 81 patients, 25 of 98 patients in the ABMT arm and
56 of 96 patients in the control arm.
Table 1. European Organization for Research and Treatment of Cancer 20901















Median age, y (range) 41 (16–65) 44 (16–63) 48 (20–65) 44 (16–65)
% male 60 63 62 62
% stage I 6 10 3 6
% stage II 37 38 24 32
% stage III 24 24 17 22
% stage IV 33 28 56 40
% B symptoms† 36 37 35 36
% positive bone marrow 15 11 30 19
% with 2 extranodal
sites
10 9 18 13
% elevated LDH 47 50 51 49
% bulky disease >10 cm 46 42 48 46
% patients 60 y old 97 98 97 97
% age-adjusted IPI
Low risk 26 24 15 21
Low–intermediate risk 43 47 41 43
Intermediate–high risk 26 22 33 28
High risk 5 7 11 8
*ABMT  autologous bone marrow transplantation; IPI  International
Prognostic Index; LDH  lactate dehydrogenase.
†Ann Arbor classification system (42).
Table 2. Pathology after central review according to the Revised European–American lymphoma classification (17)*
Pathology
ABMT arm
(n  98), No. (%)
Control arm
(n  96), No. (%)
Patients not randomly assigned
(n  117), No. (%)
All patients
(n  311), No. (%)
Diffuse large B-cell lymphoma 49 (50) 56 (58) 55 (47) 160 (51)
Primary mediastinal large B-cell lymphoma 2 (2) 2 (2) 1 (1) 5 (2)
Mantle cell lymphoma 1 (1) 3 (3) 9 (8) 13 (4)
Marginal zone B-cell lymphoma 2 (2) 3 (3) 4 (3) 9 (3)
Anaplastic large-cell lymphoma 18 (18) 11 (11) 9 (8) 38 (12)
Peripheral T and AILD-like T-cell lymphoma 1 (1) 2 (2) 5 (4) 8 (3)
Other 2 (2) 3 (3) 5 (4) 10 (3)
Unclassifiable† 19 (19) 11 (11) 20 (17) 50 (16)
Ineligible: follicular lymphoma‡ 4 (4) 2 (2) 6 (5) 12 (4)
Ineligible: Burkitt’s lymphoma‡ 3 (3) 3 (3) 6 (2)
*AILD-like  angioimmunoblastic lymphoma with dysproteinemia; ABMT  autologous bone marrow transplantation.
†Patients were considered unclassifiable if material for central review was not available or considered to be of insufficient quality.
‡Patients were registered upon the non-Hodgkin’s lymphoma classification made by the local pathologist. This might explain the inclusion of these 18 ineligible
patients. In spite of ineligibility, all patients were used in the analysis.
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Toxicity of the CHVmP/BV Regimen
All dose adjustments of the CHVmP/BV regimen were re-
corded. Of the 1634 CHVmP/BV cycles given, 74% were fol-
lowed by hematologic toxicity. The main toxicity concerned
grade 3 or 4 granulocytopenia, which was observed in 74%–85%
of the cycles throughout the whole treatment period. Grade 3 or
4 thrombocytopenia varied from 24% to 28%, and grade 3 or 4
anemia varied from 27% to 34%. Except for alopecia, nonhe-
matologic toxicity was rare with 4% at WHO grade 3 level. Two
patients developed a WHO grade 4 infection, and one patient
had a grade 4 hemorrhage. The deaths of two patients were
related to the CHVmP/BV treatment: One patient with stomach
involvement died after the first course as a result of stomach
perforation and bleeding, and the other patient died despite a
liver transplantation after exacerbation of a hepatitis B viral
infection. CHVmP/BV chemotherapy was given on time and at
a full dose in 80% of the cycles. In 15% of the cycles, a delay
of more than 1 week occurred for the combination of cyclophos-
phamide, doxorubicin, teniposide, and prednisone; a similar de-
lay occurred in 10% of the bleomycin and vincristine treatments.
Dose reductions occurred in 6% of cyclophosphamide, doxoru-
bicin, and teniposide treatments; in 1% of prednisone treatments;
in 5% of bleomycin treatments; and in 9% of vincristine treat-
ments. In the ABMT arm, 31% of cycles 4–6 were postponed
compared with 18% in the control arm, probably to enable stem
cell harvesting during that period.
ABMT, Aplasia Period, and BEAC Toxicity
Of the 60 patients given an ABMT, 47 were given bone
marrow-derived stem cells and the remaining 13 patients were
given peripheral blood-derived stem cells. A median number of
2.25 × 108 nucleated cells per kilogram was reinfused. The
median number of days in the hospital, including the 7-day
period of BEAC chemotherapy, was 25.5 days (range 11–47
days). The median number of days that patients had a granulo-
cyte count of fewer than 0.5 × 106 cells/mL was 10 days (range
 1–25 days); for a granulocyte count of fewer than 0.1 × 106
cells/mL, it was 8 days (range 2–19 days). The median num-
ber of days with fever higher than 38 °C was 4 days (range 
0–20 days). The median number of platelet transfusions was
three (range  0–29 transfusions). No death was caused by
toxicity. One grade 4 nonhematologic toxicity was caused by
septicemia. Fifteen patients developed some grade 3 toxicity
(i.e., six had an infection, four had diarrhea, four had mucositis,
and one had pulmonary complications).
Final Analysis Responses and Prognostic Factors
The responses evaluated at the end of therapy are presented in
Table 4. Given the strong predictive effect of the IPI risk factors
(26), survival curves were also related to these categories. Be-
cause 97% of the patients were younger than 60 years, the age-
adjusted IPI (26) was used; a clear delineation of these risk
groups was seen (Fig. 2). Data for the randomly assigned pa-
tients are shown in Fig. 3. If all 311 patients were taken into
account, the curve for the patients who were not randomly as-
signed to treatment was below the curve for those who were
(data not shown). Of the 98 patients in the ABMT arm, 61%
(95% confidence interval [CI]  51% to 72%) were free from
disease progression and 68% (95% CI  57% to 79%) were
alive at 5 years. For the 96 patients in the control arm, 56% (95%
CI  45% to 67%) were free from progression and 77% (95%
CI  67% to 86%) were alive at 5 years. Curves showed no
statistically significant difference. A subset analysis on the IPI
risk groups yielded similar results when the low-risk and low–
intermediate-risk groups were pooled and the intermediate–
high-risk and high-risk groups were pooled (Fig. 4). Although
the numbers were too low for statistical analysis, there was no
suggestion favoring ABMT in any risk group. Thus far, 46 pa-
tients have died, 26 in the ABMT arm and 20 in the control arm.
Table 5 presents the causes of death.
DISCUSSION
This EORTC study shows that high-dose chemotherapy after
standard chemotherapy does not improve the time to disease
progression and the overall survival of patients with aggressive
NHL. The results of this study are in line with those of several
other multicenter randomized studies that incorporated bone
marrow ablative chemotherapy for this category of patients (27–
34). However, the EORTC 20901 study essentially differs from
most other studies, which are discussed below.
The Groupe d’Etude des Lymphomes de l’Adulte (GELA)
LNH87 protocol (27) studied 464 patients, comparing high-dose
chemotherapy followed by ABMT with an intensive sequential
Table 3. Protocol adherence*
No. of patients registered (%)........................................................... 311 (100)
No. of patients off protocol between registration and
randomization (%) ..................................................................... 117 (38)
No change or disease progression after three cycles of
CHVmP/BV ............................................................................... 20 (17)
Positive bone marrow after three cycles of CHVmP/BV............ 20 (17)
No hematopoietic colony growth or other harvest problems ...... 4 (3)
Poor performance status or concurrent disease ............................ 9 (8)
Refusal for randomization............................................................. 39 (33)
Ineligibility/protocol violation/missing data ................................. 13 (11)
Administrative complications........................................................ 4 (3)
After disclosure of interim analysis.............................................. 8 (7)







Fulfilled protocol 60 (61) 82 (85) 142 (73)
Did not fulfill protocol 38 (39) 14 (15) 52 (27)
Relapse/progression during
cycles 4–6 of CHVmP/BV
12 (32) 9 (64) 21 (40)
Excessive toxicity 6 (16) 1 (7) 7 (13)
Refusal after randomization 15 (39) 15 (29)
Protocol violation 2 (14) 2 (4)
Lost to follow-up/no data 5 (13) 2 (14) 7 (13)
*CHVmP/BV  polychemotherapy regimen, given every 3 weeks (i.e., cy-
clophosphamide, doxorubicin, teniposide, and prednisone, with bleomycin and
vincristine added at mid-cycle); ABMT  autologous bone marrow transplan-
tation.
Table 4. Responses to treatment, evaluated at the end of protocol therapy
Response ABMT* arm (n  98) Control arm (n  96)
% complete remission 69 58
% partial remission 19 30
% no change 0 1
% progressive disease 11 10
% early death 0 0
% missing 1 1
*ABMT  autologous bone marrow transplantation.
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chemotherapy regimen, and found no difference in CR if all
patients were taken into account. Updated results showed that
ABMT might have been favorable for IPI intermediate–high-
risk and high-risk patients (34). However, the next GELA trial
(i.e., LNH93–3) (30) designed for these poor-risk patients (high-
dose chemotherapy after a shortened and intensified induction
phase) was prematurely closed because of primary failures and
many early relapses.
Fig. 3. Kaplan–Meier curves for patients treated according
to randomization. Data from all randomly assigned patients
are given on the basis of the intention-to-treat analysis. Up-
per panel: overall survival. Lower panel: time to disease
progression. ABMT autologous bone marrow transplan-
tation; O  observed events; N  number of patients. All
statistical tests are two-sided.
Fig. 2. Kaplan–Meier overall survival curves for all patients
(randomly assigned and not randomly assigned) according
to age-adjusted International Prognostic Index risk factors.
O  observed events; N  number of patients; L-I 
low–intermediate; H-I  high–intermediate.
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In the Dutch Organization for Hemato-oncology in Adults
(HOVON) 3 study (28), ABMT was offered only to patients in
PR after three cycles of CHOP and was given directly after the
fourth cycle. Sixty-nine patients were randomly assigned to
treatment arms, and the calculated difference of 35% between
both arms was not reached. Three other randomized trials
(32,33,36), all offering high-dose chemotherapy and ABMT af-
ter only a short induction phase, yielded similar negative results.
Gianni et al. (29) studied 98 randomly assigned patients given
either a very toxic sequential high-dose chemotherapy regimen
plus ABMT or MACOP-B (a combination of methotrexate,
doxorubicin, cyclophosphamide, vincristine, prednisone, and
bleomycin) chemotherapy. At 7 years, the ABMT arm had
higher time to disease progression and event-free survival and
showed a trend toward improvement in overall survival (29).
Finally, the Italian NHL Cooperative Study Group (31) treated
124 patients with a 12-week VACOP-B (i.e., a combination of
etoposide, doxorubicin, cyclophosphamide, vincristine, predni-
sone, and bleomycin) regimen or with DHAP (i.e., a combina-
tion of dexamethasone, high-dose cytarabine, and cisplatin) sal-
vage with high-dose chemotherapy and ABMT. No difference in
favor of the more intensive arm was observed. However, a sub-
set analysis of patients with unfavorable IPI scores suggested a
benefit for the ABMT-based therapy, which was restricted to
disease-free survival only.
In contrast to these studies, the EORTC 20901 trial treated all
patients first with a nearly full-term classical CHOP-like
therapy. As consolidation, patients in CR or PR received addi-
tional high-dose chemotherapy. To avoid imbalance in duration
between both arms, we compared the usual eight cycles of
CHVmP/BV with six cycles of CHVmP/BV followed by BEAC
and ABMT. The late randomization procedure (i.e., after cycle
3) increased the percentage of patients who could not be ran-
domly assigned or who refused to be randomly assigned, despite
informed consent at the start of therapy. Early randomization at
registration might have avoided this problem, but it would have
introduced a risk of imbalance later. Similarly, because the ac-
tual transplant took place after cycle 6, or 3 months after ran-
domization, a considerable number of patients developed con-
ditions (progressive disease or toxic effects) for which BEAC
therapy was considered to be useless or too toxic.
Importantly, the majority of the EORTC patients belonged to
the favorable IPI risk category (26). In a subset analysis of
patients in the IPI unfavorable risk categories, no differences
were seen between treatment arms. A regression survival model
would have been informative for the different risk groups, but
the small numbers of the groups in the current study did not
allow us to perform such an analysis. This analysis could be
done in future clinical trials.
At the time that the EORTC 20901 protocol was written,
a 20% difference in time to disease progression at 5 years in
favor of the ABMT therapy was expected. The Dutch HOVON
3 study (28) was even more optimistic and was estimated to
detect a 35% difference in 2-year event-free survival. Gianni et
al. (29) aimed at a 25% difference, Santini et al. (31) aimed at a
20% difference, and the GELA study (27) aimed at a 15% dif-
ference in disease-free survival at 2 years but compared the
ABMT with intensive consolidation chemotherapy. The EORTC
study was powered to detect this 20% difference because we
assumed that any smaller difference would not be clinically
relevant in view of the expected toxicity of the ABMT arm. A
20% difference would nowadays be considered to be too opti-
mistic. Moreover, given the low BEAC-related short-term tox-
icity, smaller differences would be of interest too. Presently, we
are unaware of any long-term toxicity associated with the BEAC
regimen. However, alarming new data demonstrate a high inci-
dence of secondary malignancies after ABMT procedures (37–
41). These data question the merit of submitting NHL patients to
Table 5. Causes of death
ABMT* arm (n  26),
No. (%)
Control arm (n  20),
No. (%)




Unknown 1 (4) 1 (5)
*ABMT  autologous bone marrow transplantation.
†One from respiratory insufficiency, one from a cardiovascular event, and one
from a car accident.
Fig. 4. Kaplan–Meier curves for patients treated according
to randomization arm, grouped according to the age-
adjusted International Prognostic Index (IPI) risk factors.
Data from all randomly assigned patients are given on the
basis of the intention-to-treat analysis. ABMT  autolo-
gous bone marrow transplantation; O observed events; N
 number of patients; L, low IPI risk; I intermediate IPI
risk; H  high IPI risk.
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high-dose chemotherapy if the chances of improvement are not
substantial.
In conclusion, the data from this randomized trial support the
use of a CHOP-like regimen for most patients with aggressive
NHL. Patients with IPI low risk or low–intermediate risk should
not be submitted to bone marrow ablative intensification as ini-
tial therapy. Because three randomized studies (27,29,31) found
that high-dose consolidation might be beneficial for high-risk
patients and because the outcome for these patients is still dis-
appointing, new studies investigating intensification, but only
after a full series of six to eight cycles of standard CHOP-like
treatments, need to be done. Only large intergroup randomized
studies will be statistically powerful enough to give meaningful
answers for the future.
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